정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1073 | Recruiting | Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC | Covid19 | Drug: Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol Drug: Placebo |
Phase 3 | Lebanese American University Medical Center | OTHER | 80 | All | 18 Years | LAUMCRH, Beirut, Lebanon |
| 1072 | Recruiting | Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH | Endothelial Dysfunction | Drug: Endothelial Protocol | Phase 3 | Lebanese American University Medical Center | OTHER | 70 | All | 18 Years ~ 99 Years | LAUMCRH, Beirut, Lebanon |
| 1071 | Recruiting | MANS-NRIZ Trial for COVID-19 Treatment : Extension Study | COVID-19 Pneumonia | Drug: Ivermectin,ribavirin ,nitazoxanide and zinc | Phase 3 | Mansoura University | OTHER | 100 | All | 18 Years | Mansoura University Hospital, Mansoura, Select A State Or Province, Egypt |
| 1070 | Completed | Maraviroc in Patients With Moderate and Severe COVID-19 | COVID | Drug: Maraviroc | Phase 1 | Rhode Island Hospital | OTHER | 9 | All | 18 Years ~ 99 Years | Rhode Island Hospital, Providence, Rhode Island, United States |
| 1069 | Recruiting | Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 | Coronavirus Disease 2019 | Drug: Masitinib Drug: Isoquercetin Drug: Best Supportive Care |
Phase 2 | AB Science | INDUSTRY | 200 | All | 18 Years | Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France Le Tripode, Groupe hospitalier Pellegrin CHU de Bordeaux, Bordeaux, France CHU Clermont-Ferrand: Site Gabriel-Montpied, Clermont-Ferrand, France Hopital Nord, AP-HM, Marseille, France CHR Orleans, Hopital de la Source, Orleans, France Hopital Larrey, CHU du Toulouse, Toulouse, France |
| 1068 | Not yet recruiting | Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 | Coronavirus Disease 2019 | Drug: Masitinib Mesylate Drug: Placebo |
Phase 2 | AB Science | INDUSTRY | 78 | All | 18 Years | Intensive Care Unit, CHU Gabriel-Montpied, Clermont-Ferrand, France |
| 1067 | Not yet recruiting | Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) | Viral Pneumonia | Drug: Mavrilimumab Drug: Placebo |
Phase 2 | Ospedale San Raffaele | OTHER | 50 | All | 18 Years | IRCCS Policlinico San Donato, San Donato, MI, Italy IRCCS Ospedale San Raffaele, Milano, Italy IRCCS Istituto Ortopedico Galeazzi, Milano, Italy |